USPTO serial 78246337
OPTIYIELD
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- WELLS, CHRISTOPHER
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with OPTIYIELD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
ANDREW F. ABRAMSON
ANDREW F ABRAMSON TESTA, HURWITZ & THIBEAULT, LLPHIGH ST TWR125 HIGH STBOSTON, MA 02110Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Reagents for clinical medical use; Reagents for clinical medical use in binding assays, namely assays to detect nucleic acid sequences; Reagents for clinical medical use in binding assays, namely assays to purify nucleic acid sequences; Reagents for clinical medical use in binding assays, namely assays to separate nucleic acid sequences; Reagents for clinical medical use in hybridization assays, namely assays to detect nucleic acid sequences; Reagents for clinical medical use in hybridization assays, namely assays to purify nucleic acid sequences; Reagents for clinical medical use in hybridization assays, namely assays to separate nucleic acid sequences; Reagents for clinical medical use in diagnostic electrophoresis assays; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect analytes; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to purify analytes; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to separate analytes; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect nucleic acid sequences; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to purify nucleic acid sequences; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to separate nucleic acid sequences; Reagents for clinical medical use in electrophoresis assays, namely assays to detect contamination in food products; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect contamination in blood products; Reagents for clinical medical use in electrophoresis assays, namely assays to detect biological contamination; Reagents for clinical medical use in electrophoresis assays, namely assays to detect biological contamination in food products; Reagents for clinical medical use in electrophoresis assays, namely assays to detect contamination in blood products; Reagents for clinical medical use in electrophoresis assays, namely assays to detect pathogenic contamination; Reagents for clinical medical use in electrophoresis assays, namely assays to detect food contamination; Reagents for clinical medical use in electrophoresis assays, namely assays to detect blood contamination; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect bacterial contamination in blood products; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect viral contamination in blood products; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect contamination in platelet products; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect bacterial contamination in platelet products; Reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to identify bacterial pathogens in platelet products; Reagent kits comprised of reagents for clinical medical use; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect analytes; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to purify analytes; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to separate analytes; Reagent kits comprised of reagents for clinical medical use, namely assays to detect nucleic acid sequences; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to purify nucleic acid sequences; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to separate nucleic acid sequences; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect contamination in blood products; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect bacterial contamination in blood products; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect viral contamination in blood products; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect contamination in platelet products; Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to detect bacterial contamination in platelet products; and Reagent kits comprised of reagents for clinical medical use in diagnostic electrophoresis assays, namely assays to identify bacterial pathogens | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 15, 2004 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 17, 2003 | UNPR | UNRESPONSIVE/DUPLICATE PAPER RECEIVED | — |
| Nov 17, 2003 | PAPER RECEIVED | — | |
| Oct 14, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 2, 2003 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 6, 2003 | PAPER RECEIVED | — |